Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.69 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL262171 | 1.00 | BTK (0.69) | BTKKDM1AMAOBKMT2AGAA | |
| SCHEMBL30915791 | 1.00 | BTK (0.69) | BTKKDM1AMAOBKMT2AGAA | |
| SCHEMBL262172 | 1.00 | BTK (0.69) | BTKKDM1AMAOBKMT2AGAA | |
| SCHEMBL22050935 | 0.94 | BTK (0.80) | BTKKDM1AMAOBKMT2AGAA | |
| Formic Acid SCHEMBL27879894 | 0.94 | BTK (0.61) | BTKKDM1AMAOBKMT2AGAA | |
| SCHEMBL17685322 | 0.92 | BTK (0.60) | BTKKDM1AMAOBKMT2AGAA | |
| SCHEMBL17685323 | 0.92 | BTK (0.60) | BTKKDM1AMAOBKMT2AGAA | |
| SCHEMBL182101 | 0.91 | BTK (0.82) | BTKKDM1AMAOBKMT2AGAA | |
| SCHEMBL7486096 | 0.91 | BTK (0.82) | BTKKDM1AMAOBKMT2AGAA | |
| SCHEMBL540505 | 0.91 | BTK (0.82) | BTKKDM1AMAOBKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12528814-B2 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | NURIX THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12521393-B2 | Cytotoxicity targeting chimeras for CCR2-expressing cells | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-13 | — | — | US | disclosed |
| EP-4640280-A2 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-10-29 | — | — | EP | disclosed |
| EP-4384223-B1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-10-01 | — | — | EP | disclosed |
| EP-4608810-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250228855-A1 | PYRAZINAMIDE COMPOUNDS | MASSACHUSETTS GEN HOSPITAL (US) | 2025-07-17 | — | — | US | disclosed |
| WO-2025137622-A1 | AMIDOCYCLOALKYLENE NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250136722-A1 | CYTOTOXICITY TARGETING CHIMERAS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| CN-1483024-A | Vla-4 inhibitors | ��һ��������ҩ��ʽ���� | 2004-03-17 | — | — | CN | disclosed |
| US-6693099-B2 | FOR INHIBITING TRANSPORT PROTEIN; THERAPY | THE PROCTER & GAMBLE COMPANY | 2004-02-17 | — | — | US | disclosed |
| CN-1468217-A | Aliphatic nitrogenous five-membered ring compounds | ������ҩ��ʽ���� | 2004-01-14 | — | — | CN | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
| EP-1325910-A1 | ALIPHATIC NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002079151-A1 | 3-SUBSTITUTED INDOELS OR FUSED PYRROLES AS ANTAGONISTS OF THE CHEMOKINE MCP-1 (CCR2B) RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-10 | — | — | WO | disclosed |
| US-20020123498-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS OPTIONALLY CONTAINING A QUINOLYL MOIETY FOR TREATING MULTIDRUG RESISTANCE | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. | 2002-09-05 | — | — | US | disclosed |
| US-6359134-B1 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-19 | — | — | US | disclosed |
| US-5965565-A | PIPERIDINES, PYRROLIDINES, AND HEXAHYDRO-1H-AZEPINES OF GIVEN FORMULA; CAN BE USED TO PROMOTE GROWTH OF LIVESTOCK AND IN HUMANS TREAT PHYSIOLOGICAL OR MEDICAL CONDITIONS CHARACTERIZED BY GRWOTH HORMONE DEFIENCY | MERCK & CO., INC. (US) | 1999-10-12 | — | — | US | disclosed |
| WO-1998025897-A1 | PIPERIDINES, PYRROLIDINES AND HEXAHYDRO-1H-AZEPINES PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528814-B2 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | IRAK1, IRAK2, IRAK3 | BTK 548/4885KDM1A 336/4885MAOB 4180/4885 |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | CCR2, CCR1, CCRL2 | BTK 508/4885KDM1A 761/4885MAOB 4342/4885 |
| US-20250136722-A1 | CYTOTOXICITY TARGETING CHIMERAS | HAVCR2, CD47, CYTH3 | BTK 397/4885KDM1A 4084/4885MAOB 4562/4885 |
| US-20020123498-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS OPTIONALLY CONTAINING A QUINOLYL MOIETY FOR TREATING MULTIDRUG RESISTANCE | ABCC1, ABCB1, ABCC5 | BTK 3093/4885KDM1A 4508/4885MAOB 1615/4885 |
| US-20250228855-A1 | PYRAZINAMIDE COMPOUNDS | PC, GOT2, PCK2 | BTK 1938/4885KDM1A 2454/4885MAOB 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.